Literature DB >> 12183711

Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis.

Guy Lepage1, David W Yesair, Nancy Ronco, Josée Champagne, Nathalie Bureau, Sylvain Chemtob, Denis Bérubé, Claude C Roy.   

Abstract

OBJECTIVES: To compare the absorption of a lysophosphatidylcholine, monoglyceride, and fatty acid matrix (organized lipid matrix, OLM) with that of a triacylglycerol (TG)-based fat meal in patients with cystic fibrosis (CF). STUDY
DESIGN: Five adolescents with CF and 3 control patients were given fat meals supplemented with retinyl palmitate of either OLM or TG at a 2-week interval. In a clinical trial, 73 patients with CF were randomly assigned to nutritional supplements containing either OLM or TG for a 1-year double-blind trial followed by a 6-month observation period.
RESULTS: The peak increases and areas under the curve for TG and retinyl palmitate after the fat meal were 10-fold higher after OLM than after the TG fat load and did not differ from values obtained in control patients. OLM led to better clinical outcomes in terms of energy intake from the diet, weight-for-age Z score, essential fatty acid status, vitamin E, and retinol binding protein. Height-for-age Z score and FEV(1) only reached statistical significance at the end of the 6-month observation period.
CONCLUSIONS: These results suggest that OLM is a readily absorbable source of fat and energy in CF and is an effective nutritional supplement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183711     DOI: 10.1067/mpd.2002.124305

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Barry J Maurer; C Patrick Reynolds; Min Kang; Hardeep Singh; Sonja Crandon; Anthony J Murgo; James H Doroshow
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

2.  Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Virginia A Stallings; Joan I Schall; Asim Maqbool; Maria R Mascarenhas; Belal N Alshaikh; Kelly A Dougherty; Kevin Hommel; Jamie Ryan; Okan U Elci; Walter A Shaw
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

3.  Choline supplementation alters some amino acid concentrations with no change in homocysteine in children with cystic fibrosis and pancreatic insufficiency.

Authors:  Belal Alshaikh; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Michael J Bennett; Virginia A Stallings
Journal:  Nutr Res       Date:  2015-12-29       Impact factor: 3.315

4.  Vitamin B(12) status in children with cystic fibrosis and pancreatic insufficiency.

Authors:  Asim Maqbool; Joan I Schall; Maria R Mascarenhas; Kelly A Dougherty; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-06       Impact factor: 2.839

5.  Choline Supplementation With a Structured Lipid in Children With Cystic Fibrosis: A Randomized Placebo-Controlled Trial.

Authors:  Joan I Schall; Maria R Mascarenhas; Asim Maqbool; Kelly A Dougherty; Okan Elci; Dah-Jyuu Wang; Talissa A Altes; Kevin A Hommel; Walter Shaw; Jeff Moore; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-04       Impact factor: 2.839

6.  Study design considerations for evaluating the efficacy and safety of pancreatic enzyme replacement therapy in patients with cystic fibrosis.

Authors:  Michael W Konstan; Drucy Borowitz; Nicole Mayer-Hamblett; Carlos Milla; Leslie Hendeles; Susan Murray; Richard A Kronmal; Susan Casey; Lynn M Rose; Wayne J Morgan; Bonnie W Ramsey
Journal:  Clin Investig (Lond)       Date:  2013-08

7.  Adherence to Nutritional Supplementation in Cystic Fibrosis.

Authors:  Kevin A Hommel; Joseph Rausch; Elizabeth K Towner; Joan Schall; Asim Maqbool; Maria Mascarenhas; Virginia Stallings
Journal:  J Pediatr Nurs       Date:  2019-04-18       Impact factor: 2.145

8.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

9.  Effect of a dietary intervention on growth and energy expenditure in children with cystic fibrosis.

Authors:  Veronique Groleau; Joan I Schall; Kelly A Dougherty; Norma E Latham; Asim Maqbool; Maria R Mascarenhas; Virginia A Stallings
Journal:  J Cyst Fibros       Date:  2014-02-08       Impact factor: 5.482

10.  Fat-soluble vitamins in cystic fibrosis and pancreatic insufficiency: efficacy of a nutrition intervention.

Authors:  Chiara Bertolaso; Veronique Groleau; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Norma E Latham; Kelly A Dougherty; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-04       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.